Will a time-limited love lead to a real relationship?.. Seo Ro-bin and Kim Run-gi reveal intimate couple photos [Star Issue]

*This content was translated by AI.

Seo Ro-bins, who starred in 'My Remaining Love,' has released couple photos taken with Kim Run-gi.

On the 22nd, Seo Ro-bin posted on her personal SNS: "The fragility that seemed ready to break at any moment gathered and became even stronger. Because I experienced pain, I became someone who can love myself, and now it is time to share this healthy love!"

She then shared photos taken with the cast of 'My Remaining Love,' adding a message: "To our lovely cast members, all the production staff who helped create 'My Remaining Love,' and to all viewers—thank you very much."

What stands out is the close-up shot of Kim Run-gi and Seo Ro-bin, who became the final couple. In the photo, they are posing affectionately with their faces close together. Standing as if they were a real couple, the image brings smiles to onlookers.

Seo Ro-bin, who was diagnosed with recovery from myelodysplastic syndrome, entered 'My Remaining Love' as someone who had never been in a relationship before and gave her all. Kim Run-gi, the cast member most recently diagnosed, received a stomach cancer diagnosis in November 2025 and is currently undergoing chemotherapy treatment.

The two chose each other in the final episode and became the final couple. Seo Ro-bin said, "I realized I can like Mr. Run-gi even more now," while Kim Run-gi, who is about to begin chemotherapy, responded, "Robin told me to receive treatment peacefully, and I am grateful."

In response, netizens who saw the couple photos are expressing curiosity about whether the two are still in a relationship.

Meanwhile, 'My Remaining Love,' which recently concluded, follows 2030-year-old youths who have received terminal diagnoses or experienced near-death illness journeys as they face life and love once again.

<© STARNEWS. All rights reserved. No reproduction or redistribution allowed.>

*This content was translated by AI.